Return to program book search

Session Information

SYM S050 - Psoriasis

Open admission to eligible categories, no tuition or ticket

Subject:

Date: Monday, March 04

CME Credits: 3.00

Location: Fillmore Theatre

Time: 2:00 PM - 5:00 PM

Director: Craig A. Elmets, MD, FAAD

Speakers:

  • Lawrence F. Eichenfield, MD, FAAD
  • James T. Elder, MD, PhD, FAAD
  • Boni E. Elewski, MD, FAAD
  • Joel M. Gelfand, MD, MSCE, FAAD
  • James G. Krueger, MD, PhD, FAAD
  • Mark Lebwohl, MD, FAAD - Handout
  • Kim A. Papp, MD, FAAD - Handout
  • Abby S. Van Voorhees, MD, FAAD

Learning Objectives:
Following this course, the attendee should be able to:

  • Describe the current treatment options for psoriasis and psoriatic arthritis in adults and children.
  • List new agents that are currently being evaluated as potential therapies for psoriasis, and describe the rationale for their use.
  • Manage difficult problems in psoriatic patients including nail disease, psoriasis in pregnancy and the elderly, and those with co-morbid conditions.

Description:
This symposium will review the latest approaches to psoriasis. It will address biologic and systemic agents that are currently available to treat moderate to severe psoriasis, as well as new forms of therapy that are not yet approved but are being evaluated in clinical trials. Existing topical therapies and those that are being developed to treat mild disease will also be presented. There will be a discussion of the safety of current therapies, difficult patient problems, including nail and pediatric psoriasis, and the genetics of psoriasis and psoriatic arthritis.

References:

  • Guidelines of care for the management of psoriasis and psoriatic arthritis (six parts). JAAD 58:826-50,2008; 58:581-64, 2008;60:451-85, 2009;62:114-35, 2010;65:137-74,2011.
  • Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009 Jul 30;361(5):496-509.
  • Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;445:866-73.

Schedule:

Monday, March 04
2:00 PMNails and Psoriasis / Dr. Elewski
2:20 PMPsoriasis in Pediatric Patients / Dr. Eichenfield
2:40 PMManagement of Problem Patients / Dr. Van Voorhees
3:00 PMGenetics of Psoriasis and Psoriatic Arthritis / Dr. Elder
3:20 PMSafety Signals and Systemic Psoriasis Treatment: Fine Tuning the Noise / Dr. Gelfand
3:40 PMTopical Therapy of Psoriasis: Now and in the Future / Dr. Elmets
4:00 PMCurrent Status of the Management of Moderate to Severe Psoriasis / Dr. Lebwohl
4:20 PMIL-17 and Psoriasis / Dr. Krueger
4:40 PMThe Potential of Phosphodiesterase 4 and Janus Kinase Inhibitors in the Management of Moderate to Severe Psoriasis / Dr. Papp